Welcome to our dedicated page for Sanuwave Health news (Ticker: SNWV), a resource for investors and traders seeking the latest updates and insights on Sanuwave Health stock.
Sanuwave Health, Inc. (NASDAQ: SNWV) is a medical technology company that focuses on patented, non-invasive directed energy systems used in advanced wound care and tissue regeneration. Its press releases emphasize research, development, and commercialization of medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures, as well as applications in orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
The SNWV news feed highlights quarterly and annual financial results, including revenue trends, gross margin, operating income, and non-GAAP measures such as EBITDA and Adjusted EBITDA. Investors can follow updates on record quarterly revenues, changes in revenue mix driven by UltraMIST systems and consumables, and management commentary on market conditions in the wound care space.
News items also cover business updates and reimbursement developments. Sanuwave has issued releases discussing proposed and final rules from the Centers for Medicare & Medicaid Services (CMS) for the Physician Fee Schedule, particularly reimbursement for CPT code 97610 associated with UltraMIST procedures. These updates explain how reimbursement levels for physician offices, home visits, long-term care, and hospital settings relate to the company’s expectations.
Additional coverage includes strategic and corporate events, such as a secured credit facility with JPMorgan Chase Bank, N.A. used to refinance a prior debt facility, a license and option agreement related to intravascular shockwave patents, and participation in healthcare industry conferences. The news stream also reports on governance and executive changes disclosed in Form 8-K filings, as well as announcements of conference calls to discuss financial results.
By reviewing the SNWV news page, readers can see how Sanuwave communicates its financial performance, reimbursement environment, capital structure decisions, and ongoing activities in advanced wound care and regenerative medicine.
SANUWAVE Health, Inc. (OTCQB: SNWV) announced that its common stock began trading on the OTCQB on January 30, 2023. The company specializes in the research, development, and commercialization of non-invasive medical systems designed to facilitate the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE’s innovative energy transfer technologies are aimed at enhancing wound healing and have applications in orthopedic, aesthetic, and cardiac conditions. The press release also includes forward-looking statements regarding future business developments, cautioning investors about associated risks and uncertainties.
SANUWAVE Health, Inc. (OTCPK: SNWV) reported a 12% revenue increase to $4.2 million for Q3 2022, compared to $3.7 million in Q3 2021. Year-to-date revenue surged 28.5% to approximately $11.2 million. Gross margin improved significantly to 85% for Q3, up from 58% last year. Operating loss decreased to $1.8 million from $3.4 million in the prior year, with operating expenses down 17.6% to $13.9 million for nine months. The company achieved EBITDA positivity in October, indicating potential for sustained profitable growth.
SANUWAVE Health, Inc. (OTCPK: SNWV) announced the acceptance of three abstracts showcasing its dermaPACE system for chronic wound treatment at the 2022 Fall Symposium on Advanced Wound Care. The event will be held from October 13-16, 2022, in Las Vegas. The abstracts focus on various clinical applications, including treating complex wounds related to erythromelalgia and pyoderma gangrenosum. SANUWAVE's executives will be present at booth #619, highlighting their regenerative medicine product portfolio.
SANUWAVE Health, Inc. (OTC PINK:SNWV) has announced its participation in the Microcap Rodeo's Windy City Roundup 2022 conference, taking place on October 12-13, 2022. The company will present a live investor session on October 13 at 10:30 AM (CT), with a replay available shortly after. Investors can access the presentation through SANUWAVE's investor portal. The conference will feature over 60 microcap companies, providing insights into potential investment opportunities and trends for 2023.
SANUWAVE Health announces the appointment of Dr. Toni Rinow as Chief Financial Officer, effective immediately. Dr. Rinow brings over 20 years of experience in corporate development, focusing on growth and revenue acceleration. She has previously raised over $130 million for a NASDAQ-traded wellness company. CEO Kevin Richardson emphasized that her experience aligns strategically with SANUWAVE's goals post-financing. The company is dedicated to advancing non-invasive wound care technologies that enhance natural healing processes.
SANUWAVE Health, Inc. (OTCPK: SNWV) reported significant second-quarter results for 2022, with revenues of $3.9 million, marking a 33% increase from 2021. The company successfully placed over 50 wound care systems, doubling from the previous year, and administered over 40,000 wound treatments. Gross margin improved to 72% from 64%. Operating loss decreased to $2 million vs. $4 million in 2021. SANUWAVE became current with SEC filings and is positioned for profitable growth in wound care.
SANUWAVE Health (OTCQB: SNWV) has aided football legend Jim McMahon in recovering from complications due to a surgical infection using their ENERGY FIRST devices, dermaPACE® and UltraMIST®. Following his surgery in November 2021, McMahon faced healing delays, prompting the need for effective treatment. SANUWAVE's combination therapy, initiated on April 27, 2022, successfully addressed his wound, which was healed within three weeks. Kevin Richardson, CEO, expressed pride in their technology's impact on improving wound care.
SANUWAVE Health (SNWV) reported a 75% increase in estimated revenue for June year-over-year, attributed to heightened recurring revenue and successful conversions from evaluations. The sales funnel rose by 9% to $23 million, and system trials grew by 5%, totaling 109 trials. The company is closely monitoring these figures for the second quarter and expects some volatility ahead. This positive trend in sales metrics underlines SANUWAVE's commitment to enhancing its wound care portfolio.
SANUWAVE Health (OTC: SNWV) announced a strong performance for May 2022, reporting an estimated revenue increase of 96% year-over-year. The sales funnel also saw a 5% increase, totaling $21.1 million, while system trials rose by 2%, reaching 103 active trials. These trends suggest significant growth potential for the second quarter, although the company anticipates some volatility in these figures going forward. SANUWAVE specializes in innovative wound care and regenerative medicine, focusing on non-invasive medical systems.
SANUWAVE Health reported a significant 100% revenue increase year-over-year for Q1 2022, totaling $3.2 million, up from $2.1 million in 2021. The first quarter's sales were driven by their ENERGY FIRST device line, as the prior year's biologics sales are no longer included. Additionally, April saw a 9% increase in the sales funnel, reaching $19.9 million, while system trials rose 5% to 101. Despite potential volatility, these metrics provide visibility into future revenue growth as the company navigates opportunities in the wound care market.
FAQ
What is the current stock price of Sanuwave Health (SNWV)?
What is the market cap of Sanuwave Health (SNWV)?
